© 2022 MJH Life Sciences and Urology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Urology Times. All rights reserved.
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer, reviews the potential treatment options, including PARP inhibitors, and highlights the importance of genetic testing when selecting treatment regimens.
May 23rd 2022
Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.
Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.
An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.
A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.
Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).
An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.
Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.
A review of whether PARP inhibitors such as olaparib could potentially be used in earlier lines of therapy for mCRPC.
Neal Shore, MD, FACS, muses about the unmet needs in metastatic prostate cancer treatment and shares clinical pearls for community oncologists.